Plain-English translation of NCT06934252 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called , given as a subcutaneous injection (under the skin), to see if it is safe and works well for people with moderate-to-severe atopic dermatitis. The trial will first test the medication in healthy adults at different dose levels, then move to testing it in patients who actually have the condition. Researchers want to understand how the body processes this medication and whether it helps reduce symptoms.
Atopic dermatitis (eczema) is a chronic skin condition that causes intense itching, redness, and discomfort, and current treatments don't work well for everyone. This trial is testing whether this new injectable medication could offer a better treatment option for people with moderate-to-severe disease.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive injections under your skin either once (if in the healthy volunteer portion) or every 4 weeks for 8–12 weeks (if you have eczema). You will have regular follow-up visits where the research team checks your health, takes blood samples, and (if you have eczema) evaluates how your skin is improving. The entire study lasts between 4 and 6 months depending on which part of the trial you're in.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Australia